The stock of Sientra Inc (NASDAQ:SIEN) is a huge mover today! About 117,765 shares traded hands. Sientra Inc (NASDAQ:SIEN) has risen 5.59% since March 29, 2016 and is uptrending. It has outperformed by 2.11% the S&P500.
The move comes after 5 months positive chart setup for the $126.48M company. It was reported on Oct, 31 by Barchart.com. We have $20.10 PT which if reached, will make NASDAQ:SIEN worth $201.10M more.
Analysts await Sientra Inc (NASDAQ:SIEN) to report earnings on November, 21. They expect $-0.55 EPS, down 27.91% or $0.12 from last year’s $-0.43 per share. After $-0.56 actual EPS reported by Sientra Inc for the previous quarter, Wall Street now forecasts -1.79% EPS growth.
Sientra Inc (NASDAQ:SIEN) Ratings Coverage
Out of 3 analysts covering Sientra (NASDAQ:SIEN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Sientra has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating given on Thursday, February 11 by Stifel Nicolaus. The firm has “Market Perform” rating by William Blair given on Wednesday, August 10.
According to Zacks Investment Research, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California.”
Insitutional Activity: The institutional sentiment decreased to 0.34 in 2016 Q2. Its down 0.86, from 1.2 in 2016Q1. The ratio turned negative, as 20 funds sold all Sientra Inc shares owned while 24 reduced positions. 8 funds bought stakes while 7 increased positions. They now own 12.46 million shares or 8.28% less from 13.58 million shares in 2016Q1.
Blackrock Invest Mngmt Ltd Liability reported 2,301 shares or 0% of all its holdings. Moreover, Barclays Public Ltd has 0% invested in Sientra Inc (NASDAQ:SIEN) for 826 shares. The North Carolina-based Financial Bank Of America Corporation De has invested 0% in Sientra Inc (NASDAQ:SIEN). Royal Commercial Bank Of Canada owns 900 shares or 0% of their US portfolio. Gilder Gagnon Howe And Lc last reported 129,354 shares in the company. Blackrock Fund Advisors holds 0% of its portfolio in Sientra Inc (NASDAQ:SIEN) for 32,761 shares. Abingworth Limited Liability Partnership accumulated 2.20 million shares or 15.15% of the stock. Amici Cap Ltd Liability has 25,000 shares for 0.03% of their US portfolio. Jpmorgan Chase And Com accumulated 0% or 1,217 shares. Creative Planning has 1,000 shares for 0% of their US portfolio. Bridgeway Cap Management reported 194,500 shares or 0.02% of all its holdings. Bamco Inc Ny has 50,000 shares for 0% of their US portfolio. Clarus Ventures Ltd Liability Com accumulated 15.72% or 2.73M shares. The Germany-based Deutsche Natl Bank Ag has invested 0% in Sientra Inc (NASDAQ:SIEN). New York State Common Retirement Fund holds 0% or 1,800 shares in its portfolio.
More important recent Sientra Inc (NASDAQ:SIEN) news were published by: Marketwatch.com which released: “Sientra Inc. NASDAQ: SIEN” on June 04, 2011, also Quotes.Wsj.com published article titled: “Sientra Inc. SIEN (US: Nasdaq)”, Bloomberg.com published: “Sientra Breast Implants Stuck in Limbo After Supplier’s Setbacks” on October 16, 2015. More interesting news about Sientra Inc (NASDAQ:SIEN) was released by: Businesswire.com and their article: “GPM Announces Investigation of Alleged Fraud By Sientra, Inc.” with publication date: September 24, 2015.
SIEN Company Profile
Sientra, Inc., incorporated on August 29, 2003, is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Firm sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. The Company’s breast implants are primarily used in elective procedures, which are generally performed on a cash pay basis. The Company’s breast implants incorporate one or more differentiated technologies, including a cohesive silicone gel and texturing branded TRUE Texture. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Firm also offers breast tissue expanders and a range of other aesthetic and specialty products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.